A comprehensive protocol-based triaging and decision making at the point of care in patients with COVID-19 presenting with acute myocardial injury is necessary to reduce provider anxiety and confusion.
Timely primary percutaneous coronary intervention should remain to be first line treatment for patients presenting to the emergency department with acute STEMI during the COVID-19 pandemic.
A novel score to stratify risk associated with acute chest pain was found to outperform 2 commonly used scoring systems in predicting the 30-day risk for major adverse cardiovascular events.
The pathologic and clinical features of coronavirus disease 19 may be mechanistically linked to an increased risk for disseminated intravascular coagulation and propensity for diffuse alveolar hemorrhage.
An increase in hospitalizations for acute myocardial infarction-rheumatoid arthritis was observed between 2002 and 2016, with rheumatoid arthritis found to be independently associated with lower in-hospital mortality in patients with acute myocardial infarction.
ST-segment elevation was observed in a cohort of patients presenting to New York City hospitals with COVID-19.
The majority of patients with acute coronary syndrome treated with statins were found to have low-density lipoproteins-cholesterol levels above those recommended by current guidelines.
The treatment of patients with dual antiplatelet therapy after a percutaneous coronary intervention was found to be associated with a reduction in de novo atherothrombotic ischemic events.
Aboriginal and Torres Strait Islander status may predict death in individuals with acute coronary syndrome.
The addition of the ezetimibe to simvastatin in patients with a recent acute coronary syndrome was not found to be associated with an increased incidence of patient-reported muscle complaints.